Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
Novel Nonstimulant Approved for ADHD Treatment in Adults
06/29/2022
The US Food and Drug Administration has approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults, maker Supernus Pharmaceuticals recently...
The US Food and Drug Administration has approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults, maker Supernus Pharmaceuticals recently...
The US Food and Drug...
06/29/2022
Psych Congress Network
News
Despite Rise in Mental Health Disorders, no Increase in Access to Formal Psych Care for People with Borderline Intellectual Impairment
06/28/2022
While people with borderline intellectual impairment showed increasing prevalence of several mental health disorders over a decade and a half, access to formal psychiatric care did not increase, according to a study published in the Journal...
While people with borderline intellectual impairment showed increasing prevalence of several mental health disorders over a decade and a half, access to formal psychiatric care did not increase, according to a study published in the Journal...
While people with borderline...
06/28/2022
Psych Congress Network
News
Novel Group Exposure Therapy Improves Adolescent Anxiety Over Time
06/28/2022
An adolescent anxiety disorder treatment program that combines group cognitive behavioral therapy (CBT) with high degrees of exposure practice, including family and school involvement, is showing superior results compared to other studied...
An adolescent anxiety disorder treatment program that combines group cognitive behavioral therapy (CBT) with high degrees of exposure practice, including family and school involvement, is showing superior results compared to other studied...
An adolescent anxiety disorder...
06/28/2022
Psych Congress Network

Advertisement

News
FDA Subcommittee Votes Against Pimavanserin for Alzheimer Disease Psychosis Therapy
06/28/2022
FDA Psychopharmacologic Drugs Advisory Committee (PDAC) voted 9 to 3 that there is not sufficient evidence pimavanserin is effective in the treatment of hallucinations and delusions associated with Alzheimer disease psychosis.
FDA Psychopharmacologic Drugs Advisory Committee (PDAC) voted 9 to 3 that there is not sufficient evidence pimavanserin is effective in the treatment of hallucinations and delusions associated with Alzheimer disease psychosis.
FDA Psychopharmacologic Drugs...
06/28/2022
Psych Congress Network
News
Cybin Receives FDA Clearance for Clinical Trial of Psilocybin Analog to Treat MDD
06/28/2022
The Toronto-based company’s CYB003 becomes the first novel psilocybin analog to enter clinical development.
The Toronto-based company’s CYB003 becomes the first novel psilocybin analog to enter clinical development.
The Toronto-based company’s...
06/28/2022
Psych Congress Network
News
Report: VA Engages in Experimental Psychedelic Therapy for PTSD
06/27/2022
The Department of Veterans Affairs (VA) has begun offering psychedelic substances to clinical trial patients, according to a recent report in the New York Times.
The Department of Veterans Affairs (VA) has begun offering psychedelic substances to clinical trial patients, according to a recent report in the New York Times.
The Department of Veterans...
06/27/2022
Psych Congress Network

Advertisement

News
Significant Intervention Opportunities Missed in Alcohol-Related Liver Disease Deaths
06/23/2022
Numerous chances for care providers to identify alcohol misuse going unnoticed, researchers say.
Numerous chances for care providers to identify alcohol misuse going unnoticed, researchers say.
Numerous chances for care...
06/23/2022
Psych Congress Network
News
Comorbid Sleep Disorders Common in Chronic Migraine Patients
06/22/2022
Patients with chronic migraine, as compared to episodic migraine, displayed higher rates of comorbid sleep disorders, including obstructive sleep apnea (OSA) and insomnia.
Patients with chronic migraine, as compared to episodic migraine, displayed higher rates of comorbid sleep disorders, including obstructive sleep apnea (OSA) and insomnia.
Patients with chronic migraine,...
06/22/2022
Neurology
News
Distinct Gene Expression Signature Identified in Group of Patients With MDD
06/20/2022
Patients with MDD who died by suicide had a gene expression signature distinct from other patients with MDD that included genes involved in stress response and polyamine metabolism, immune response, and telomere maintenance.
Patients with MDD who died by suicide had a gene expression signature distinct from other patients with MDD that included genes involved in stress response and polyamine metabolism, immune response, and telomere maintenance.
Patients with MDD who died by...
06/20/2022
Psych Congress Network

Advertisement

News
Chronic PTSD, Comorbid Depression Symptoms Improved With Ketamine
06/16/2022
Repeated ketamine infusions over 2 weeks were associated with large-magnitude improvement in post-traumatic stress disorder (PTSD) symptoms compared with a psychoactive placebo in individuals with chronic PTSD.
Repeated ketamine infusions over 2 weeks were associated with large-magnitude improvement in post-traumatic stress disorder (PTSD) symptoms compared with a psychoactive placebo in individuals with chronic PTSD.
Repeated ketamine infusions over...
06/16/2022
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use